Reported Earnings • Apr 23
First quarter 2026 earnings released: EPS: CN¥0.08 (vs CN¥0.13 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.08 (down from CN¥0.13 in 1Q 2025). Revenue: CN¥260.0m (up 21% from 1Q 2025). Net income: CN¥32.5m (down 40% from 1Q 2025). Profit margin: 13% (down from 25% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings. Announcement • Apr 23
Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, May 13, 2026 Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, May 13, 2026, at 14:00 China Standard Time. Location: 22F, No. 8, Qiuzhi East Road, Longhua District, Shenzhen, Guangdong China Announcement • Mar 30
Shenzhen Lifotronic Technology Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 New Risk • Mar 04
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 30% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 04
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.43 (down from CN¥0.81 in FY 2024). Revenue: CN¥1.04b (down 9.6% from FY 2024). Net income: CN¥186.1m (down 46% from FY 2024). Profit margin: 18% (down from 30% in FY 2024). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 38%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Announcement • Dec 26
Shenzhen Lifotronic Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: CN¥0.099 (vs CN¥0.20 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.099 (down from CN¥0.20 in 3Q 2024). Revenue: CN¥256.0m (down 4.1% from 3Q 2024). Net income: CN¥41.5m (down 52% from 3Q 2024). Profit margin: 16% (down from 32% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Shenzhen Lifotronic Technology Co., Ltd. to Report Q3, 2025 Results on Oct 29, 2025 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025 Announcement • Jun 30
Shenzhen Lifotronic Technology Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Major Estimate Revision • Apr 17
Consensus revenue estimates fall by 18% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥1.54b to CN¥1.26b. EPS estimate fell from CN¥1.15 to CN¥0.90 per share. Net income forecast to grow 12% next year vs 56% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥22.31 to CN¥19.09. Share price fell 2.8% to CN¥13.66 over the past week. Price Target Changed • Apr 12
Price target decreased by 14% to CN¥19.09 Down from CN¥22.31, the current price target is an average from 2 analysts. New target price is 38% above last closing price of CN¥13.86. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.90 for next year compared to CN¥0.81 last year. Reported Earnings • Apr 11
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.81 (up from CN¥0.77 in FY 2023). Revenue: CN¥1.15b (flat on FY 2023). Net income: CN¥345.4m (up 5.1% from FY 2023). Profit margin: 30% (up from 29% in FY 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Apr 11
Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, May 07, 2025 Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, May 07, 2025, at 14:00 China Standard Time. Location: 22F, No. 8, Qiuzhi East Road, Longhua District, Shenzhen, Guangdong China Announcement • Mar 28
Shenzhen Lifotronic Technology Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Feb 21
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.81 (up from CN¥0.77 in FY 2023). Revenue: CN¥1.15b (flat on FY 2023). Net income: CN¥346.7m (up 5.5% from FY 2023). Profit margin: 30% (up from 29% in FY 2023). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 15%. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Dec 27
Shenzhen Lifotronic Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 11, 2025 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 11, 2025 Price Target Changed • Nov 02
Price target increased by 7.5% to CN¥22.45 Up from CN¥20.87, the current price target is an average from 3 analysts. New target price is 37% above last closing price of CN¥16.38. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥0.96 for next year compared to CN¥0.77 last year. Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.16 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.16 in 3Q 2023). Revenue: CN¥266.9m (up 6.4% from 3Q 2023). Net income: CN¥85.5m (up 22% from 3Q 2023). Profit margin: 32% (up from 28% in 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥15.08, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 17% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.4% average weekly change). Announcement • Sep 30
Shenzhen Lifotronic Technology Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥14.84, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past three years. Price Target Changed • Sep 02
Price target decreased by 12% to CN¥20.87 Down from CN¥23.60, the current price target is an average from 3 analysts. New target price is 63% above last closing price of CN¥12.82. Stock is down 33% over the past year. The company is forecast to post earnings per share of CN¥0.97 for next year compared to CN¥0.77 last year. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.15 (up from CN¥0.11 in 2Q 2023). Revenue: CN¥284.2m (up 1.3% from 2Q 2023). Net income: CN¥64.7m (up 39% from 2Q 2023). Profit margin: 23% (up from 17% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Announcement • Jun 29
Shenzhen Lifotronic Technology Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Upcoming Dividend • Apr 29
Upcoming dividend of CN¥0.28 per share Eligible shareholders must have bought the stock before 06 May 2024. Payment date: 06 May 2024. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Chinese dividend payers (2.4%). Lower than average of industry peers (1.7%). Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.21 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.25 (up from CN¥0.21 in 1Q 2023). Revenue: CN¥305.7m (up 10% from 1Q 2023). Net income: CN¥107.2m (up 22% from 1Q 2023). Profit margin: 35% (up from 32% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 29
Shenzhen Lifotronic Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 22
Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, Apr 12, 2024 Shenzhen Lifotronic Technology Co., Ltd., Annual General Meeting, Apr 12, 2024, at 14:00 China Standard Time. Location: Building 1, No. 2, Zhanghua Road, Songshan Lake, Dongguan, Guangdong China Reported Earnings • Feb 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.77 (up from CN¥0.60 in FY 2022). Revenue: CN¥1.15b (up 17% from FY 2022). Net income: CN¥327.5m (up 30% from FY 2022). Profit margin: 29% (up from 26% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥15.13, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.36 per share. Buying Opportunity • Jan 08
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be CN¥25.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 73% in 2 years. Earnings is forecast to grow by 79% in the next 2 years. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥21.89, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 9.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.26 per share. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.16 (up from CN¥0.12 in 3Q 2022). Revenue: CN¥250.7m (up 11% from 3Q 2022). Net income: CN¥70.4m (up 31% from 3Q 2022). Profit margin: 28% (up from 24% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.079 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.11 (up from CN¥0.079 in 2Q 2022). Revenue: CN¥280.6m (up 19% from 2Q 2022). Net income: CN¥46.4m (up 43% from 2Q 2022). Profit margin: 17% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 29
First quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.16 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.16 in 1Q 2022). Revenue: CN¥277.8m (up 32% from 1Q 2022). Net income: CN¥88.1m (up 31% from 1Q 2022). Profit margin: 32% (in line with 1Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.59 (up from CN¥0.45 in FY 2021). Revenue: CN¥983.0m (up 26% from FY 2021). Net income: CN¥249.4m (up 31% from FY 2021). Profit margin: 25% (in line with FY 2021). Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) also missed analyst estimates by 1.7%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥23.79, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 31% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 12 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Employee Representative Supervisor Bin Huo is the most experienced director on the board, commencing their role in 2020. Independent Director Shiqiang Chen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.09 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.12 (up from CN¥0.09 in 3Q 2021). Revenue: CN¥226.6m (up 21% from 3Q 2021). Net income: CN¥53.6m (up 35% from 3Q 2021). Profit margin: 24% (up from 21% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥19.28, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 4.8% over the past year. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.07 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.079 (up from CN¥0.07 in 2Q 2021). Revenue: CN¥236.9m (up 24% from 2Q 2021). Net income: CN¥32.4m (up 14% from 2Q 2021). Profit margin: 14% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 38%, compared to a 26% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥18.36, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 30% over the past year. Reported Earnings • Apr 17
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: CN¥0.16 (up from CN¥0.13 in 1Q 2021). Revenue: CN¥210.0m (up 28% from 1Q 2021). Net income: CN¥67.1m (up 24% from 1Q 2021). Profit margin: 32% (in line with 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Reported Earnings • Feb 28
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: CN¥0.45 (up from CN¥0.34 in FY 2020). Revenue: CN¥778.1m (up 41% from FY 2020). Net income: CN¥190.0m (up 32% from FY 2020). Profit margin: 24% (down from 26% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.2%. Over the next year, revenue is forecast to grow 37%, compared to a 24% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 25% share price decline to CN¥18.79, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Medical Equipment industry in China. Total loss to shareholders of 15% over the past year. Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥22.56, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 28x in the Medical Equipment industry in China. Total loss to shareholders of 8.7% over the past year. Reported Earnings • Oct 23
Third quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.06 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥188.0m (up 40% from 3Q 2020). Net income: CN¥39.8m (up 71% from 3Q 2020). Profit margin: 21% (up from 17% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Aug 09
Second quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.071 in 2Q 2020) The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥191.6m (up 40% from 2Q 2020). Net income: CN¥28.4m (down 11% from 2Q 2020). Profit margin: 15% (down from 23% in 2Q 2020). Reported Earnings • Apr 18
First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.09 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥164.4m (up 35% from 1Q 2020). Net income: CN¥54.0m (up 43% from 1Q 2020). Profit margin: 33% (up from 31% in 1Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS CN¥0.34 (vs CN¥0.26 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥553.8m (up 31% from FY 2019). Net income: CN¥143.9m (up 43% from FY 2019). Profit margin: 26% (up from 24% in FY 2019). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 22
New 90-day high: CN¥24.00 The company is up 16% from its price of CN¥20.74 on 24 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 14% over the same period. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥18.23, the stock is trading at a trailing P/E ratio of 59x, down from the previous P/E ratio of 70.3x. This compares to an average P/E of 42x in the Medical Equipment industry in China. Total returns to shareholders over the past year are 1.8%. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥18.77 The company is down 35% from its price of CN¥28.93 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 12
New 90-day low: CN¥18.85 The company is down 25% from its price of CN¥25.25 on 11 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 1.0% over the same period. Is New 90 Day High Low • Oct 31
New 90-day low: CN¥24.90 The company is down 25% from its price of CN¥33.11 on 31 July 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 7.0% over the same period. Reported Earnings • Oct 21
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥127.4m, up 24% from the prior year. Total revenue was CN¥516.4m over the last 12 months, up 29% from the prior year. Announcement • Oct 16
Shenzhen Lifotronic Technology Co., Ltd. to Report Q3, 2020 Results on Oct 17, 2020 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report Q3, 2020 results on Oct 17, 2020 Announcement • Jul 09
Shenzhen Lifotronic Technology Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020 Shenzhen Lifotronic Technology Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020